The bioreactor from Merck Millipore is suitable for biopharmaceutical applications and expands the company’s portfolio of single-use processing systems which cover cell culture and ultrafiltration/diafiltration. It features SensorReady technology which makes it possible to configure process monitoring at the point of use, reducing the need to customise bioreactor process containers and enabling the integration of new sensor technologies. Merck says that it can be easier installed and the system is available as a turnkey system complete with Finesse automation or as a modular system.
“With this introduction, biopharmaceutical manufacturers now have a wider range of scalable single-use bioreactors offered by Merck Millipore, from three litres to two hundred litres, to support their needs from process development to clinical scale,” said Paul Chapman, vice president of biopharm process solutions.
